# US 2006/0153819 A1 · Bone marrow stromal cells for immunoprotection of transplanted neural stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153819 A1
- Document ID: US20060153819A1
- Status: Published application
- Kind: A1
- Application number: 11/328,976
- Filed: 2006-01-10
- Published: 2006-07-13
- Earliest claimed: 2005-01-11
- Assignees: Cognate Therapeutics, Inc.
- Inventors: Kevin McIntosh
- Web page: https://patentgrep.com/patent/US20060153819A1

## CPC

- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61K 35/35: Fat tissue; Adipocytes; Stromal cells; Connective tissues (adipose-derived stem cells A61K35/28; collagen A61K38/39)
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention encompasses methods and compositions for reducing an immune response to a transplant recipient receiving NSCs by treating said recipient with an amount of bone marrow stromal effective to reduce or inhibit host rejection of the NSCs.

## Claims

### Claim 1

A method of treating a transplant recipient, wherein said transplant is a neural stem cell (NSC), to reduce in said recipient an immune response of effector cells against an alloantigen to said effector cells, the method comprising;
administering to a transplant recipient, bone marrow stromal cells in an amount effective to reduce an immune response of effector cells against an alloantigen to said effector cells, whereby in the transplant recipient said effector cells have a reduced immune response against said alloantigen.

### Claim 2 (depends on 1)

The method of claim 1, wherein said effector cells are T cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein said T cells are from a donor and said alloantigen is from a recipient.

### Claim 4 (depends on 2)

The method of claim 2, wherein said T cells are from a recipient and said alloantigen is from a donor.

### Claim 5 (depends on 2)

The method of claim 2, wherein said T cells are present in the transplant.

### Claim 6 (depends on 1)

The method of claim 1, wherein prior to said administering to a transplant recipient bone marrow stromal cells, said bone marrow stromal cells have been expanded in culture.

### Claim 7 (depends on 1)

The method of claim 1, wherein said effector cells are T cells activated prior to administration of bone marrow stromal cells, and further wherein said immune response is the reactivation of said T cells from the donor.

### Claim 8 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are administered to the transplant recipient to treat rejection of the transplant by the recipient.

### Claim 9 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are human bone marrow stromal cells.

### Claim 10 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are rat bone marrow stromal cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein said NSCs are human NSCs.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering to said recipient an immunosuppressive agent.

### Claim 13 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are administered to the recipient prior to said transplant.

### Claim 14 (depends on 1)

The method of claim 1, wherein said bone marrow stromal stem cells are administered to the recipient concurrently with said transplant.

### Claim 15 (depends on 14)

The method of claim 14, wherein said bone marrow stromal cells are administered as part of the transplant.

### Claim 16 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are administered to the recipient subsequent to the transplantation of the transplant.

### Claim 17 (depends on 1)

The method of claim 1, wherein said bone marrow stromal cells are administered intravenously to the recipient.

### Claim 18 (depends on 1)

The method of claim 1, wherein said effector cells are cells of a recipient of said donor transplant.

### Claim 19 (depends on 1)

The method of claim 1, wherein said bone stromal cells are genetically modified.

### Claim 20

A method for treating a transplant recipient, wherein said transplant is a neural stem cell (NSC), to reduce in said recipient an immune response of effector cells against an alloantigen to the effector cells, comprising:
transplanting to a transplant recipient NSCs with bone marrow stromal cells in an amount effective to reduce an immune response of effector cells against an alloantigen to the effector cells, whereby in the transplant recipient the effector cells have a reduced immune response against the alloantigen.

### Claim 21 (depends on 20)

The method of claim 20 wherein said effector cells are T cells.
